公开(公告)号：US20240166618A1

公开(公告)日：2024-05-23

申请号：US18281127

申请日：2022-03-14

Applicant: GILGAMESH PHARMACEUTICALS, INC.

Inventor： Andrew Carry KRUEGEL

IPC: C07D317/58 ,  A61K31/138 ,  A61K31/145 ,  A61K31/277 ,  A61K31/36 ,  A61P25/22 ,  A61P25/24 ,  C07C217/60 ,  C07C255/59 ,  C07C323/32

CPC classification number: C07D317/58 ,  A61K31/138 ,  A61K31/145 ,  A61K31/277 ,  A61K31/36 ,  A61P25/22 ,  A61P25/24 ,  C07C217/60 ,  C07C255/59 ,  C07C323/32

Abstract: The present disclosure provides phenalkylamine compounds and their use in treating medical disorders, such as psychiatric diseases and disorders. Pharmaceutical compositions and methods of making various phenalkylamine compounds are provided.

公开(公告)号：US20230331750A1

公开(公告)日：2023-10-19

申请号：US18303613

申请日：2023-04-20

Applicant: LIER CHEMICAL CO., LTD.

Inventor： Yongjiang LIU ,  Lei Zhou ,  Wei Zeng ,  Min Xu ,  Ke Cheng

IPC: C07F9/54 ,  C07C237/06 ,  C07C323/32

CPC classification number: C07F9/5407 ,  C07C237/06 ,  C07C323/32

Abstract: A preparation method for glufosinate or a salt, an enantiomer or a mixture of enantiomers in all ratios thereof, the method being especially suitable for the preparation of glufosinate, and greatly shortening steps in an existing preparation process. Especially in the preparation of L-glufosinate, the product can effectively retain the ee value of the raw materials.

公开(公告)号：US20230312464A1

公开(公告)日：2023-10-05

申请号：US18041731

申请日：2021-08-18

Applicant: CYBIN IRL LIMITED

Inventor： Alex BELSER ,  Clinton E. CANAL ,  Brett J. GREENE ,  Joshua A. HARTSEL ,  Alex NIVOROZHKIN ,  Michael PALFREYMAN

IPC: C07C323/32 ,  C07C323/20 ,  C07C217/60

CPC classification number: C07C323/32 ,  C07C323/20 ,  C07C217/60 ,  C07B2200/05

Abstract: There are disclosed deuterated 2C—X phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

公开(公告)号：US20230278994A1

公开(公告)日：2023-09-07

申请号：US18008116

申请日：2021-06-01

Applicant: Bayer Aktiengesellschaft

Inventor： Julie GEIST ,  Anthony MILLET ,  Cyril MONTAGNE ,  Lionel NICOLAS ,  Tomoki TSUCHIYA ,  Vincent THOMAS

IPC: C07D413/04 ,  C07D403/04 ,  C07D239/34 ,  C07D405/12 ,  C07D409/12 ,  C07D413/14 ,  C07D403/12 ,  C07C211/29 ,  C07C323/32 ,  C07C233/11 ,  C07D333/20

CPC classification number: C07D413/04 ,  C07D403/04 ,  C07D239/34 ,  C07D405/12 ,  C07D409/12 ,  C07D413/14 ,  C07D403/12 ,  C07C211/29 ,  C07C323/32 ,  C07C233/11 ,  C07D333/20

Abstract: The present disclosure relates to heterocyclyl pyrimidine and heterocyclyl triazine compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.

公开(公告)号：US11737992B2

公开(公告)日：2023-08-29

申请号：US17169662

申请日：2021-02-08

Applicant: Enzo Therapeutics, Inc. ,  Virginia Commonwealth University

Inventor： Sarah Spiegel ,  Robert Elliot Zipkin ,  Jeffrey Kroll Adams

IPC: A61K31/135 ,  A61P25/04 ,  A61P11/06 ,  A61K31/40 ,  C07C323/32 ,  C07D263/06 ,  C07D295/092 ,  C07C215/28 ,  C07C217/64 ,  C07C233/18

CPC classification number: A61K31/135 ,  A61K31/40 ,  A61P11/06 ,  A61P25/04 ,  C07C215/28 ,  C07C217/64 ,  C07C233/18 ,  C07C323/32 ,  C07D263/06 ,  C07D295/092

Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in the treatment of neuropathic pain.

公开(公告)号：US10945971B2

公开(公告)日：2021-03-16

申请号：US16813961

申请日：2020-03-10

Applicant: Enzo Therapeutics, Inc. ,  Virginia Commonwealth University

Inventor： Sarah Spiegel ,  Robert Elliot Zipkin ,  Jeffrey Kroll Adams

IPC: A61K31/135 ,  A61P9/00 ,  A61P7/00 ,  A61P11/06 ,  A61K31/40 ,  C07C323/32 ,  C07D263/06 ,  C07D295/092 ,  C07C215/28 ,  C07C217/64 ,  C07C233/18

Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating ischemic diseases such as myocardial infarction and stroke.

公开(公告)号：US20190111007A1

公开(公告)日：2019-04-18

申请号：US16199337

申请日：2018-11-26

Applicant: Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc. ,  Virginia Commonwealth University

Inventor： Sarah Spiegel ,  Robert Elliot Zipkin ,  Jeffrey Kroll Adams

IPC: A61K31/135 ,  C07C233/18 ,  C07C217/64 ,  C07D295/092 ,  C07C215/28 ,  C07C323/32 ,  A61K31/40 ,  C07D263/06

Abstract: Provided are inhibitors of sphingosine kinase Type I and their use in the treatment of asthma, among other indications and diseases.

公开(公告)号：US20190055338A1

公开(公告)日：2019-02-21

申请号：US16078104

申请日：2017-03-30

Applicant: 3M INNOVATIVE PROPERTIES COMPANY

Inventor： Benjamin J. Anderson

IPC: C08G16/02 ,  C07C255/54 ,  C07C323/32 ,  C08L61/00

Abstract: A resin blend is provided including a blend of resorcinol diphthalonitrile ether resin and a bisphenol M diphthalonitrile ether resin. Another resin blend is provided including a blend of resorcinol diphthalonitrile ether resin and a bisphenol T diphthalonitrile ether resin. The resin blends prior to cure have more favorable processing and curing properties compared to the resorcinol diphthalonitrile resin alone, enabling greater ease in manufacturing.

公开(公告)号：US10166204B2

公开(公告)日：2019-01-01

申请号：US15954131

申请日：2018-04-16

Applicant: Enzo Therapeutics, Inc. ,  Virginia Commonwealth University

Inventor： Sarah Spiegel ,  Robert Elliot Zipkin ,  Jeffrey Kroll Adams

IPC: A61K31/135 ,  A61P1/04 ,  A61K31/40 ,  C07C215/28 ,  C07C323/32 ,  C07D263/06 ,  C07D295/092 ,  C07C217/64 ,  C07C233/18

Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).

公开(公告)号：US20180346407A1

公开(公告)日：2018-12-06

申请号：US15967080

申请日：2018-04-30

Applicant: Acucela Inc.

Inventor： Claes Olof BAVIK ,  Susan Hayes HENRY ,  Ryo KUBOTA ,  Vladimir A. KUKSA

IPC: C07C215/08 ,  A61K31/765 ,  A61K31/35 ,  A61K31/137 ,  A61K45/06 ,  A61K31/138 ,  C07C323/32 ,  C07C217/20 ,  C07C211/27 ,  C07D309/06

Abstract: Methods are provided herein for the treatment of ophthalmic diseases or conditions such as an ophthalmic disease or disorder associated with diabetes in a patient. Also provided herein are methods of treating retinopathy of prematurity in a patient. Further, provided herein are methods for treating wet age-related macular degeneration in a patient. The methods comprise administration of compounds disclosed herein to a patient in need thereof that inhibit or slow one or more signs or symptoms of such conditions.